Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Total Liabilities (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Total Liabilities for 16 consecutive years, with $13.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 12.05% to $13.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.6 million, a 12.05% increase, with the full-year FY2024 number at $15.6 million, up 22.35% from a year prior.
  • Total Liabilities was $13.6 million for Q3 2025 at Plus Therapeutics, up from $7.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $35.7 million in Q1 2025 to a low of $7.3 million in Q2 2025.
  • A 5-year average of $13.3 million and a median of $11.6 million in 2022 define the central range for Total Liabilities.
  • Biggest YoY gain for Total Liabilities was 241.34% in 2025; the steepest drop was 61.16% in 2025.
  • Plus Therapeutics' Total Liabilities stood at $10.0 million in 2021, then skyrocketed by 74.31% to $17.4 million in 2022, then decreased by 26.9% to $12.7 million in 2023, then rose by 22.35% to $15.6 million in 2024, then decreased by 12.62% to $13.6 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Total Liabilities are $13.6 million (Q3 2025), $7.3 million (Q2 2025), and $35.7 million (Q1 2025).